Authors: Sharon Salt, Editor
In this week’s industry news round-up we set the focus on Alzheimer’s disease (AD), with yet another clinical trial termination announced from vTv Therapeutics Inc. (NC, USA). On the other hand, Alzheimer’s researchers have proposed a novel framework for defining the disease, which focuses more on biological changes than clinical symptoms.
Find out more in our selected highlights:
Azeliragon fails in Phase III trial for Alzheimer’s diseaseRestricted Content / Members Only